Tumor Genomic Profiling denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for tumor genomic profiling are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Tumor Genomic Profiling as Duplicate Therapy — and How to Appeal

Tumor genomic profiling — including comprehensive genomic sequencing and large multi-gene panels — characterizes the molecular landscape of a cancer to guide targeted treatment. Cigna may deny a request as a "duplicate" when its records show a prior genomic test was already performed and approved for the same patient, concluding that the new test would merely reproduce information already available.

### Why This Denial Happens

Duplicate-therapy denials on genomic testing occur most commonly when a prior test was billed and paid within a recent lookback period, or when Cigna's utilization management vendor (which may include an external lab benefit manager) flags the test code as recently utilized. The policy rationale is that the prior result should still be clinically actionable. This reasoning breaks down when the clinical circumstances have changed — for example, disease progression, a new metastatic lesion requiring fresh biopsy, histologic transformation, or a shift in treatment intent.

### Why It Is Appealable

A duplicate-therapy denial assumes the prior test remains clinically equivalent to what is being requested today. When the tumor has evolved, a new tissue site is being evaluated, or the prior test did not include the genomic regions relevant to the current therapy decision, the premise of duplication fails. Documenting the clinical distinction is the core of a successful appeal.

### Federal Appeal Framework

• Internal appeal: Submit within the timeframe on the denial notice (commonly 180 days for ACA-compliant plans). Cigna must respond within 30 days for pre-service and 60 days for post-service claims.
• External review (ACA §2719): After an internal denial, you may request review by an Independent Review Organization. The filing window is generally around four months from the final adverse determination. The IRO's decision is binding on Cigna.
• ERISA §503: For employer-sponsored plans, ERISA guarantees a full-and-fair review. You may request the complete administrative record, including the criteria Cigna applied.
• Expedited review: If delay would seriously jeopardize health or ability to receive needed treatment, an expedited review is available with a decision typically required within 72 hours.

### Documentation to Gather

1. Current pathology and clinical notes — documentation confirming the cancer's current state: stage, site, histology, and any changes since the prior test. 2. Prior test records — the original test report with date, panel type, tissue source, and results, plus a clear explanation of why those results do not answer the current clinical question. 3. Clinical event justifying re-testing — chart documentation of disease progression, new biopsy, histologic change, or therapeutic context shift. 4. Ordering oncologist's medical-necessity letter — a signed letter articulating the specific clinical question this test will answer and why the prior result cannot substitute. 5. Applicable guideline reference — the treating oncologist should reference the relevant NCCN guideline or equivalent professional society recommendation.

### Criteria-Mapping Structure

Download Cigna's current medical coverage policy for the applicable test code from cigna.com. List each coverage criterion verbatim. Build a two-column table: policy requirement on the left, chart documentation satisfying it on the right. Address the duplicate-therapy criterion specifically by identifying the clinical distinction between the prior test and the current request. This structure compels a criterion-by-criterion review and prevents the appeal from being dismissed on the same blanket rationale.